Tocilizumab, an antibody which blocks the classical IL-6 pathway by binding to the IL-6 receptor is approved for the treatment of rheumatoid arthritis (69) and was also tested in an animal model for the treatment of acute pancreatitis with promising results (70). Here, IL6 is linked to acute pancreatitis.